Ten months ago, when MDS Proteomics held an opening ceremony at its flagship facility in Toronto, a panel of scientists and managers trumpeted the advent of a new age in drug discovery that proteomics would make manifest. It was a giddy time for the subsidiary of Canadian health care giant MDS, which had sunk millions into assembling an impressive suite of mass spectrometry, computational prowess, and scientific expertise.